VolitionRx Ltd 2025年季度报告

VOLITIONRX LIMITED (Exact name of registrant as specified in its charter) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).☐Yes☒No As of May 7, 2025, there were103,022,677shares of the registrant’s $0.001 par value common stock issued and outstanding. Except as otherwise indicated by the context, references in this Quarterly Report on Form 10-Q to the “Company,” “VolitionRx,”“Volition,” “we,” “us,” and “our” are references to VolitionRx Limited and its wholly owned subsidiaries, Volition Global ServicesSRL, Singapore Volition Pte. Limited, Belgian Volition SRL, Volition Diagnostics UK Limited, Volition America, Inc., and itsmajority-owned subsidiary, Volition Veterinary Diagnostics Development LLC. Additionally, unless otherwise specified, all references NucleosomicsTM,, Capture-PCRTM, Nu.Q®and Capture-SeqTMand their respective logos are trademarks and/or service marks ofVolitionRx and its subsidiaries. All other trademarks, service marks and trade names referred to herein are the property of theirrespective owners. Table of Contents CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS This Quarterly Report on Form 10-Q for the quarterly period endedMarch 31, 2025, (this “Report”) contains forward-lookingstatements within the meaning of Section27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section21E of theSecurities Exchange Act of 1934, as amended (the “Exchange Act”), which statements are subject to considerable risks anduncertainties. These forward-looking statements are intended to qualify for the safe harbor from liability established by the PrivateSecurities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this Report or incorporatedby reference into this Report are forward-looking statements.We have attempted to identify forward-looking statements by using wordssuch as “aim,” “anticipate,” “believe,” “continue,” “could,” “estimate(s),” “expect,” “forecast(s),” “goal,” “intend,” “may,”“plan(s),” “potential,” “project,” “seek,” “should,” “strategy,” “will,”and other forms of these words or similar words orexpressions or the negative thereof (although not all forward-looking statements contain these words).In particular, forward-looking We have based our forward-looking statements on our current assumptions, expectations and projections about trends affecting ourbusiness and industry and other future events. Although we do not make forward-looking statements unless we believe we have areasonable basis for doing so, we cannot guarantee their accuracy. Forward-looking statements are subject to substantial known andunknown risks and uncertainties that could cause our future business, financial condition, results of operations or performance, to Some significant factors that may impact our estimates and forward-looking statements include, but are not limited to: ·Our inability to generate any significant revenues or achieve profitability;·Our need to raise additional capital in the future;·Our expansion of our product development and sales and marketing capabilities could give rise to difficulties in managingour growth;·Our dependence on third-party distributors;·Our limited experience with sales and marketing;·The possibility that we may not be able to continue to operate, as indicated by the “going concern” opinion from ourauditors;·Our ability to successfully develop, manufacture, market, and sell our future products; ·Our ability to timely obtain necessary regulatory clearances or approvals to distribute and market our future products;·The acceptance by the marketplace of our future products;·The highly competitive and rapidly changing nature of the diagnostics market;·Protection of ou